Reata’s kidney med bardoxolone delivers in phase 3, teeing up FDA filing By Michael Tattory| 2019-11-18T11:05:30-04:00 November 11th, 2019|News|Comments Off on Reata’s kidney med bardoxolone delivers in phase 3, teeing up FDA filing Share This Story, Choose Your Platform! FacebookTwitterLinkedinGoogle+VkEmail About the Author: Michael Tattory Related Posts Surprise man battling rare disease helping researchers come up with treatment Gallery Surprise man battling rare disease helping researchers come up with treatment Driving Drug Discovery Using Patients’ Immune Response Gallery Driving Drug Discovery Using Patients’ Immune Response IPO Window, Recession, Trade War & More — 5 Biopharma Finance Experts Share Their Perspectives For 2020 Gallery IPO Window, Recession, Trade War & More — 5 Biopharma Finance Experts Share Their Perspectives For 2020 Pfizer, Novartis lead $2 billion spending spree on gene therapy production Gallery Pfizer, Novartis lead $2 billion spending spree on gene therapy production ProQR: Developing RNA Therapies for Rare Genetic Disorders Gallery ProQR: Developing RNA Therapies for Rare Genetic Disorders
